Statistics for UroGen Pharma (id:6692 URGN)

Valuation metrics

Market cap

487.40M

Enterprise value

356.35M

Trailing P/E (ttm)

-3.35

Forward P/E

-4.34

PEG ratio

-4.34

Price/Sales (ttm)

5.45

Price/Book (mrq)

19.09

Enterprise Value/Revenue

3.99

Enterprise Value/EBITDA

-4.28

Overview

Shares outstanding

42.20M

Float

24.53M

Shares short

6.60M

% Held by insiders

0.09%

% Held by institutions

0.89%

Average volume (10 days)

432.15K

Average volume (90 days)

Price summary

52-Week low

10.60

52-Week high

20.70

52-Week change

-7.22%

Beta

1.13

50-Day moving average

12.45

200-Day moving average

14.59

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-129.11%

Operating margin

-69.61%

Operational effectiveness

Return on assets

-21.12%

Return on equity

156.79%

Income statement

Revenue (ttm)

2.39

Revenue per share (ttm)

2.39

Quarterly revenue growth (yoy)

Gross profit (ttm)

73.35M

EBITDA

-83,282,000.00

Net income to common (ttm)

-115,378,000.00

Diluted EPS (ttm)

-3.02

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

249.58M

Total cash per share (mrq)

5.91

Total debt (mrq)

122.75M

Total Debt/Equity (mrq)

481.07

Current ratio (mrq)

900.00%

Book value per share (mrq)

0.60

Cash flow

Cash flow statement

-96,143,000.00

Levered free cash flow (LFCF)

-49,254,500.00